Simplification to Efavirenz-Tenofovir DF-Emtricitabine
ADONE Trial
**Simplification to Efavirenz-Tenofovir DF-Emtricitabine**

**ADONE: Study Design**

### Study Design: ADONE Study

- **Background**: Prospective, comparative, open-label study evaluating the advantages of switching to one-pill-once a day with efavirenz-tenofovir DF-emtricitabine

- **Inclusion Criteria (n = 212)**
  - Stable on ART with EFV + TDF + FTC (or 3TC)
  - HIV RNA < 50 copies/mL

- **Treatment (Switch) Arm**
  - Efavirenz-Tenofovir DF-Emtricitabine

### Timeline

- **Week 0**
- **Week 24**

**EFV-TDF-FTC QD**

(n = 212)

Simplification to Efavirenz-Tenofovir DF-Emtricitabine
ADONE: Result

Week 48 Virologic Response (ITT Analysis, M=F)

Simplification to Efavirenz-Tenofovir DF-Emtricitabine
ADONE: Result

Week 48 CD4 Cell Count Response

Simplification to Efavirenz-Tenofovir DF-Emtricitabine ADONE: Result

Improvement in Adherence Following Switch to One-Pill-Once-A-Day

Interpretation: “By substituting a one-pill once-a-day HAART, we observed an improvement of both adherence and QoL while maintaining high virologic and immunologic efficacy. HAART simplicity is an added value that favors adherence and may improve long-term success.”
Acknowledgment

The National HIV Curriculum is an AIDS Education and Training Center (AETC) Program resource funded by the United States Health Resources and Services Administration. The project is led by the University of Washington and the AETC National Coordinating Resource Center.

The content in this slide set does not represent the official views of the U.S. Department of Health and Human Services, Health Resources & Services Administration.